Investment and innovation in women’s healthcare remain insufficient. Globally, research and development in this area is estimated to account for less than five percent of overall pharmaceutical R&D, resulting in limited treatment options for the future, and at the same time creating opportunities for innovative companies willing to invest. Against this backdrop, Richter and Fuji have signed a Business Collaboration Agreement that will strengthen joint efforts in business development and R&D within gynecology, a strategic priority area for both parties.

Leveraging the experience and expertise each organization has cultivated, the partnership will jointly identify, assess, and pursue the acquisition or in‑licensing of promising external drug candidates worldwide. Together with internal projects, these initiatives aim to accelerate innovation and deliver advanced therapeutic solutions in women’s health globally.

To promote innovation in gynecology, Richter has recently established an original research hub for drug discovery and development in Belgium as well as strengthened its Budapest-based R&D activities. This hub will play a pivotal role in advancing the joint development efforts of Richter and Fuji.